Ground News

Understand Every Side.

Gilead Sciences image

News about Gilead Sciences

Stay current with all the latest and breaking news about Gilead Sciences, compare headlines and perspectives between news sources on stories happening today. In total, 38stories have been published about Gilead Sciences which Ground News has aggregated in the past 3 months.

Covered Most By

modernreaders.com

themarketsdaily.com

Suggest a source

Local News Publishers

Suggest a source

Looking for a source we don't already have? Suggest one here.

Top Gilead Sciences News

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

Breast Cancer · United States

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

70% Center coverage: 17 sources

Gilead Sciences´ Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday. The data is likely to change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said.See the Story

U.S. Aid Helped Two African Countries Rein in HIV. Then Came Trump

U.S. Aid Helped Two African Countries Rein in HIV. Then Came Trump

Coverage: 5 sources

In Lesotho and Eswatini, treatment and prevention cutbacks are hitting pregnant women, children, and teens especially hard See the Story

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Gilead Sciences · Enid

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Coverage: 2 sources

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering ...See the Story

New Link Connects Herpes to Alzheimer's. Here's What We Know.

100% Center coverage: 1 sources

A new study has found the herpes simplex virus type 1 (HSV-1), which causes cold sores, may be linked to the development of Alzheimer's disease.Alzheimer's Disease See the Story

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Regeneron Pharmaceuticals (NASDAQ:REGN)

100% Center coverage: 2 sources

Blueprint Medicines, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals, Gilead Sciences, D-Wave Quantum, and Johnson & Johnson are the seven Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are equity shares of companies that research, develop, manufacture and market prescription drugs, vaccines and other medical treatments. Their performance is driven by factors such as …Novo Nordisk · United States See the Story

Gilead’s Phase III trial for breast cancer therapy meets primary goal

Gilead Sciences’ randomised, global Phase III ASCENT-03 trial of Trodelvy (sacituzumab govitecan-hziy) has met its primary endpoint.The post Gilead’s Phase III trial for breast cancer therapy meets primary goal appeared first on Clinical Trials Arena.Gilead Sciences Read Article

Breakthrough Clinical Trial: Trodelvy Achieves First Major Advance in 20 Years for Early-Stage Breast Cancer Treatment

New Phase 3 data reveals significant progression-free survival benefit in first-line metastatic TNBC treatment. First major advance in two decades. See full results.Breast Cancer · United States See the Story

Soviero Asset Management LP Cuts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Soviero Asset Management LP lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 13.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 20,000 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the period. Soviero Asset Management LP’s holdings in Gilead […]Gilead Sciences · United States See the Story

Cancer Research Center Celebrates Topping-Out New Foster City Facility

A combined team from Suffolk Construction and Gilead Sciences celebrated the topping out of the new state-of-the-art facility in Foster City. The project, at 331 Lakeside Drive, was previously reported on by SF YIMBY in 2023. Gensler is responsible for the architecture and design.Gilead Sciences · New Albany See the Story

Gilead reports final outcomes from trial of bulevirtide for chronic HDV

Gilead Sciences has reported final outcomes from the Phase III MYR301 trial of bulevirtide for adults with chronic hepatitis delta virus.The post Gilead reports final outcomes from trial of bulevirtide for chronic HDV appeared first on Clinical Trials Arena.Gilead Sciences Read Article

Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions

75% Center coverage: 4 sources

Click here to view this article from thepress.net.Gilead Sciences · United States See the Story

Breaking News Topics Related to Gilead Sciences